Limits...
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ - Cancer (2014)

Bottom Line: M1 demonstrated that the initial increase in patient-reported fatigue with sunitinib was worst during cycle 1, with mean values numerically better at subsequent cycles; most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant.The majority of HRQoL scores were better with sunitinib versus IFN-α for the same CTCAE fatigue grade.Patients reported worse fatigue during the first sunitinib cycle.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Show MeSH

Related in: MedlinePlus

Mean (A) Functional Assessment of Cancer Therapy-Kidney Symptom Index–Disease-Related Symptoms (subscale) (FKSI-DRS) score, (B) FKSI item “I have lack of energy” score, and (C) FKSI item “I feel fatigued” score are shown by adverse event (AE) fatigue grade with sunitinib and interferon-α (IFN-α). Higher scores indicate better outcome (better health-related quality of life or fewer symptoms).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4231253&req=5

fig04: Mean (A) Functional Assessment of Cancer Therapy-Kidney Symptom Index–Disease-Related Symptoms (subscale) (FKSI-DRS) score, (B) FKSI item “I have lack of energy” score, and (C) FKSI item “I feel fatigued” score are shown by adverse event (AE) fatigue grade with sunitinib and interferon-α (IFN-α). Higher scores indicate better outcome (better health-related quality of life or fewer symptoms).

Mentions: An independent but complementary analysis demonstrated that the relationship between most HRQoL outcomes and CTCAE fatigue was close to linear in both treatment groups, with lower (worse) HRQoL scores on most measures corresponding to a higher mean fatigue grade (Figs. 4 and 5), except for HRQoL measures not directly linked with fatigue (ie, the FACT-G Social/Family Well-Being subscore and the FKSI items “I have bone pain,” “I have been coughing,” “I am sleeping well,” “I worry that my condition will get worse,” and “I am bothered by fevers”). For nearly all outcomes (FKSI, FKSI-DRS, FACT-G, and EQ-5D [data not shown]), regardless of whether they were aggregated or single items, patients treated with sunitinib had noticeably better HRQoL scores than patients in the IFN-α group for the same CTCAE severity of fatigue. For example, the FKSI-DRS subscale and FKSI items “I have a lack of energy” and “I feel fatigued” scores were both higher with sunitinib than with IFN-α at each CTCAE grade of fatigue (Figs. 4A-4C). The same pattern was observed for the relationship between the total FACT-G score and the FACT-G Physical Well-Being and Social/Family Well-Being subscores (Figs. 5A-5C).


Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ - Cancer (2014)

Mean (A) Functional Assessment of Cancer Therapy-Kidney Symptom Index–Disease-Related Symptoms (subscale) (FKSI-DRS) score, (B) FKSI item “I have lack of energy” score, and (C) FKSI item “I feel fatigued” score are shown by adverse event (AE) fatigue grade with sunitinib and interferon-α (IFN-α). Higher scores indicate better outcome (better health-related quality of life or fewer symptoms).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4231253&req=5

fig04: Mean (A) Functional Assessment of Cancer Therapy-Kidney Symptom Index–Disease-Related Symptoms (subscale) (FKSI-DRS) score, (B) FKSI item “I have lack of energy” score, and (C) FKSI item “I feel fatigued” score are shown by adverse event (AE) fatigue grade with sunitinib and interferon-α (IFN-α). Higher scores indicate better outcome (better health-related quality of life or fewer symptoms).
Mentions: An independent but complementary analysis demonstrated that the relationship between most HRQoL outcomes and CTCAE fatigue was close to linear in both treatment groups, with lower (worse) HRQoL scores on most measures corresponding to a higher mean fatigue grade (Figs. 4 and 5), except for HRQoL measures not directly linked with fatigue (ie, the FACT-G Social/Family Well-Being subscore and the FKSI items “I have bone pain,” “I have been coughing,” “I am sleeping well,” “I worry that my condition will get worse,” and “I am bothered by fevers”). For nearly all outcomes (FKSI, FKSI-DRS, FACT-G, and EQ-5D [data not shown]), regardless of whether they were aggregated or single items, patients treated with sunitinib had noticeably better HRQoL scores than patients in the IFN-α group for the same CTCAE severity of fatigue. For example, the FKSI-DRS subscale and FKSI items “I have a lack of energy” and “I feel fatigued” scores were both higher with sunitinib than with IFN-α at each CTCAE grade of fatigue (Figs. 4A-4C). The same pattern was observed for the relationship between the total FACT-G score and the FACT-G Physical Well-Being and Social/Family Well-Being subscores (Figs. 5A-5C).

Bottom Line: M1 demonstrated that the initial increase in patient-reported fatigue with sunitinib was worst during cycle 1, with mean values numerically better at subsequent cycles; most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant.The majority of HRQoL scores were better with sunitinib versus IFN-α for the same CTCAE fatigue grade.Patients reported worse fatigue during the first sunitinib cycle.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Show MeSH
Related in: MedlinePlus